Morpholine-4-sulfonyl chloride → HCID 178527580, compound
Reaction equation
Cl.[O:2]1[C:6]2[CH:7]=[CH:8][CH:9]=[C:10]([CH:11]3[CH2:16][CH2:15][N:14]([CH2:17][CH2:18][C@H:19]4[CH2:24][CH2:23][C@H:22]([NH2:25])[CH2:21][CH2:20]4)[CH2:13][CH2:12]3)[C:5]=2[O:4][CH2:3]1.[N:26]1([S:32](Cl)(=[O:34])=[O:33])[CH2:31][CH2:30][O:29][CH2:28][CH2:27]1>>[O:2]1[C:6]2[CH:7]=[CH:8][CH:9]=[C:10]([CH:11]3[CH2:16][CH2:15][N:14]([CH2:17][CH2:18][C@H:19]4[CH2:20][CH2:21][C@H:22]([NH:25][S:32]([N:26]5[CH2:31][CH2:30][O:29][CH2:28][CH2:27]5)(=[O:34])=[O:33])[CH2:23][CH2:24]4)[CH2:13][CH2:12]3)[C:5]=2[O:4][CH2:3]1Participants
3
Procedure
The title compound, white solid (5.4 mg, 13.2%), MS (ISP) m/z=480.2 [(M+H)+], was prepared in accordance with the general method of example 78 from Trans-4-[2-(4-Benzo[1,3]dioxol-4-yl-piperidin-1-yl)-ethyl]-cyclohexylamine hydrochloride (intermediate A) (31.2 mg, 85 mmol) and morpholine-4-sulfonyl chloride.
Sources & evidence
- ORD record
- ord-239babd76cdd414a8e6215d7bf34c664
- Source dataset
- uspto-grants-2013_12
- Patent number
- US08598357B2
Reaction notes
Loading…